JAMP Pharma Corporation issues a voluntary recall of one (1) lot of its Atorvastatin tablets, 40 mg, 100-format for lot D10776B (Health Canada's Public advisory RA-64513)

BOUCHERVILLE, QC, Aug. 29, 2022 /CNW Telbec/ - JAMP Pharma Corporation ("JAMP") is voluntarily, on a precautionary basis, recalling one product lot of Atorvastatin tablets, 40 mg, 100-format (lot D10776B) at the retail level (type 1 recall).

On August 25^th, 2022, JAMP initiated with Health Canada a voluntary recall of ^PrJAMP-Atorvastatin 40mg 100-format tablets (lot D10776B) due to a possible mislabeling of certain bottles in the lot, which may be labeled as JAMP-Atorvastatin Calcium 10mg 500-format tablets (DIN 02504197), when they should be labeled as JAMP-Atorvastatin Calcium 40mg, 100-format tablets (DIN 02504219).

JAMP takes compliance matters seriously and takes no chances when it comes to patient safety. This is why, out of an abundance of caution, we are recalling the entire lot of ^PrJAMP-Atorvastatin Calcium 40 mg (lot D10776B). An investigation is underway with the manufacturing site to understand the factors that may have led to the current situation. As a result of this investigation, preventive measures and corrective actions will be put in place with the manufacturing site.

Atorvastatin is a prescription drug used to treat high cholesterol and other fats (such as triglycerides) in the blood to prevent cardiovascular diseases, some that can lead to heart attacks.

Risk statement: There is a risk associated with the use of high-dose statins, such as atorvastatin, in patients with predisposing factors for rhabdomyolysis. This risk increases with the concentration of atorvastatin in the body. Therefore, for these patients, a higher than prescribed dose of atorvastatin may increase the risk of developing this medically important condition.

JAMP has already notified its wholesalers and distributors and is arranging the return of the affected lot.

Consumers with questions regarding this recall can contact JAMP Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at [email protected]. Consumers should contact their doctor or healthcare provider if they have experienced any problems that may be related to taking or using the drug product affected by this recall. Adverse reactions or any other issues experienced with the use of this product may be reported to Health Canada online, by using the form found at this website: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html.

About JAMP Pharma Corporation

JAMP Pharma is part of the JAMP Pharma Group, a privately-owned Québec company headquartered in Montreal. The JAMP Pharma Group is present in all pharmaceutical market segments, from over-the-counter products to biosimilars. JAMP Pharma has a portfolio of nearly 300 generic molecules and leads the Canadian pharmaceutical industry in terms of new generic product launches¹. It also ranks among the country's top companies in terms of annual prescription volume² according to IQVIA. The Group also has a Wampole-Laboratoire Suisse Division with more than 160 over-the-counter products, including a wide range of vitamins, supplements, and natural products, as well as prescription and branded products from its subsidiary Orimed Pharma. The BIOJAMP division recently introduced its first biosimilar product and has the ambition to offer one of the most complete offers on the Canadian market.

¹ Pharmaceutical manufacturers with the highest volume of product launches in Canada from 2016 to 2021. Based in part on data obtained under licence from IQVIA Solutions Canada Inc., concerning the following information service: Canadian Drug Store and Hospital Audit, moving annual total from January to December 2016 to 2021. All Rights Reserved. The statement expressed herein is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliated or subsidiary entities.

² Pharmaceutical manufacturers with the highest volume of prescriptions reported in Canada from January to August 2021. Based in part on data obtained under licence from IQVIA Solutions Canada Inc., concerning the following information service: CompuScript, January to August 2021. All Rights Reserved. The statement expressed herein is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliated or subsidiary entities.

SOURCE JAMP Pharma Corporation

For media inquiries, Alexandra Lewicki, Director of Marketing & Communications, [email protected]